Golden State Equity Partners’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.05K Buy
+43
New +$1.2K ﹤0.01% 1989
2026
Q2
– Sell
-25
Closed -$595 – 472
2026
Q1
$595 Buy
+25
New +$694 ﹤0.01% 1859
2024
Q4
– Sell
-260
Closed -$6.37K – 488
2024
Q3
$6.37K Buy
+260
New +$6.72K ﹤0.01% 739
2022
Q1
$555K Buy
9,690
+3,090
+47% +$203K 0.28% 101
2021
Q4
$526K Buy
+6,600
New +$565K 0.27% 88

Other funds holding BEAM

Golden State Equity Partners's BEAM Position: Q3 2026 in Review

Golden State Equity Partners opened a new position in Beam Therapeutics (BEAM) in Q3 2026: 43 shares worth $1.05K. The stake represents ﹤0.01% of the portfolio and ranks #1989 among its holdings. This is a return to the name: Golden State Equity Partners previously reported a position in BEAM as recently as Q1 2026.

Golden State Equity Partners first reported a position in BEAM in Q4 2021 and has held it in 5 quarters since. The position peaked at $555K in Q1 2022. 264 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.

  • Golden State Equity Partners held 43 shares of Beam Therapeutics worth $1.05K as of Q3 2026.
  • Beam Therapeutics was a new Golden State Equity Partners position in Q3 2026.
  • Beam Therapeutics made up ﹤0.01% of Golden State Equity Partners's portfolio in Q3 2026, its #1989 holding.
  • Golden State Equity Partners first reported a position in Beam Therapeutics in Q4 2021 and has held it in 5 quarters since.
  • Golden State Equity Partners's Beam Therapeutics position peaked at $555K in Q1 2022.
  • 264 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.

Based on Golden State Equity Partners's 13F filing for Q3 2026, filed 3 Nov 2026.